|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,880.00 INR | -0.37% |
|
-3.01% | +26.80% |
| 07-16 | Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges | RE |
| 07-09 | India's Dr Reddy's says semaglutide shipping disruption to last until at least late October | RE |
| Market Cap | 1,864B 19.51B 17.12B 15.94B 14.66B 27.48B 27.96B 189B 74.02B 924B 73.23B 71.65B 3,193B | P/E 2027 * |
70.8x | P/E 2028 * | 52.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1,978B 20.7B 18.17B 16.92B 15.56B 29.17B 29.67B 201B 78.57B 981B 77.72B 76.05B 3,389B | EV / Sales 2027 * |
10.4x | EV / Sales 2028 * | 9.09x |
| Free-Float |
36.66% | Yield 2027 * |
0.62% | Yield 2028 * | 0.7% |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | -0.34% | ||
| 1 week | -3.01% | ||
| Current month | +5.66% | ||
| 1 month | +4.81% | ||
| 3 months | +15.37% | ||
| 6 months | +24.22% | ||
| Current year | +26.80% |
| 1 week | 4,857.2 |  | 5,078.5 |
| 1 month | 4,574.3 | | 5,085.8 |
| Current year | 3,695 | | 5,085.8 |
| 1 year | 3,480.6 | | 5,085.8 |
| 3 years | 1,772.05 | | 5,085.8 |
| 5 years | 1,242.08 | | 5,085.8 |
| 10 years | 570.98 | | 5,085.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 01/08/2025 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 01/09/2018 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 30/07/2014 | |
| Director/Board Member | 46 | 08/02/2018 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 07/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.37% | -3.01% | - | - | 19.51B | |
| +1.93% | +3.85% | +51.05% | +166.24% | 1,089B | |
| +0.29% | +6.43% | +60.47% | +52.87% | 643B | |
| +2.45% | +2.77% | +39.61% | +74.48% | 465B | |
| +2.17% | +10.22% | +41.17% | +36.56% | 359B | |
| +1.46% | +3.87% | +39.70% | +44.49% | 303B | |
| +0.40% | +3.59% | +19.93% | +17.02% | 267B | |
| +2.73% | +3.50% | -25.66% | -36.53% | 226B | |
| +4.48% | +7.33% | +30.47% | +66.31% | 212B | |
| +2.91% | +3.10% | +18.84% | +74.76% | 167B | |
| Average | +1.93% | +5.07% | +30.62% | +55.13% | 414.57B | |
| Weighted average by Cap. | +1.95% | +5.14% | +39.89% | +80.14% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 190B 1.99B 1.75B 1.63B 1.5B 2.81B 2.86B 19.33B 7.57B 94.46B 7.48B 7.32B 326B | 214B 2.24B 1.97B 1.83B 1.68B 3.16B 3.21B 21.72B 8.5B 106B 8.41B 8.23B 367B |
| Net income | 24.86B 260M 228M 213M 196M 367M 373M 2.52B 988M 12.33B 977M 956M 42.6B | 33.98B 356M 312M 291M 267M 501M 510M 3.45B 1.35B 16.85B 1.34B 1.31B 58.22B |
| Net Debt | 114B 1.2B 1.05B 978M 900M 1.69B 1.72B 11.61B 4.54B 56.73B 4.49B 4.4B 196B | 82.03B 859M 754M 702M 645M 1.21B 1.23B 8.32B 3.26B 40.68B 3.22B 3.15B 141B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/07/26 | ₹4,880.00 | -0.37% | 226,134 |
| 28/07/26 | ₹4,898.30 | -2.41% | 549,152 |
| 27/07/26 | ₹5,019.50 | +1.17% | 267,708 |
| 24/07/26 | ₹4,961.50 | -2.05% | 262,189 |
| 23/07/26 | ₹5,065.20 | +0.63% | 423,979 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TORNTPHARM Stock
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
